Navigation Links
MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
Date:11/7/2007

leBrook intends to actively continue its strategic evaluation process, alternatives for which include, but are not limited to, the possible sale of some or all of the Company's assets, partnering or other collaboration agreements, or a merger or other strategic transaction. There can be no assurance that the exploration of strategic alternatives at that time will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms.

Transaction Terms

At the transaction closing on November 7, 2007, MiddleBrook sold certain assets, and assigned certain intellectual property rights, relating only to its existing cephalexin business, excluding cephalexin PULSYS, to Deerfield for $7.5 million, less a $500,000 payment to Deerfield. Pursuant to a consignment of those assets and license of those intellectual property rights back to the Company, the Company will continue to operate its existing cephalexin business, subject to royalty payments to Deerfield of 20% of net sales, which declines to a single digit royalty as the agreement matures. In addition, the Company granted to Deerfield a six-year warrant to purchase 3.0 million shares of the Company's common stock at $1.38, the closing market price on November 7, 2007.

If and when the Company receives approval of its Amoxicillin PULSYS New Drug Application, it may require Deerfield to acquire and license certain intellectual property rights relating only to the Company's cephalexin PULSYS business for a payment of $2.5 million. Pursuant to a sublicense of those intellectual property rights back to the Company, the Company will continue to operate its cephalexin PULSYS business. Cephalexin PULSYS is not approved for marketing by the FDA.

Deerfield also granted the Company the right to repurchase all assets and rights acquired and licensed by Deerfield for a flat purchase price of $14.0 million, if the Company has required Deerfield to
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... 2015 , ... In an article published July 30th by the ... New Orleans, highlighting a security firm that is tasked with providing supplemental protection. Called ... who worked with the city to provide private security when it is needed in ...
(Date:8/27/2015)... ... August 27, 2015 , ... Allegheny General Hospital (AGH), part ... medical centers in the United States to receive international recognition for an advanced, ... Extracorporeal Life Support Organization (ELSO) , an international consortium of healthcare institutions dedicated ...
(Date:8/27/2015)... Michigan (PRWEB) , ... August 27, 2015 , ... On ... returned for the second year as sponsor of the “Music With A Mission” benefit ... raise money for music education programs in the underfunded school districts of Mendon and ...
(Date:8/27/2015)... ... 27, 2015 , ... Dr. Jennifer Arnold, co-star of “The Little Couple” and ... 3rd Annual MPN Heroes™ recognition event on Friday, Dec. 4, prior to ... honoring eight heroes who have made significant contributions in the field of rare blood ...
(Date:8/27/2015)... ... August 27, 2015 , ... Infocast is ... October 27-29, 2015 in San Jose, CA. The first event dedicated to ... the void that exists where battery development and energy storage innovation are concerned. ...
Breaking Medicine News(10 mins):Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2
... 1960s, surgeons experimented by transplanting chimpanzee organs into humans in ... a baboon heart and survived 20 days. Since then, doctors// ... organs, tissues and cells to treat various diseases, all with ... surrounding cross-species transplant -- also known as xenotransplantation. ...
... common treatment option for HIV patients is associated with ... a new study. However, researchers say the benefit of ... for most patients. ,Combination antiretroviral therapy substantially ... AIDS. Before this therapy was available, the annual mortality ...
... for centuries, doctors say. But only recently has it been ... migraines or neck- and head-squeezing tension headaches //that are present ... think it sounds like just another excuse to skip school. ... freshman from St. Cloud, Minnesota, know how serious the condition ...
... is a common health problem worldwide. Both osteoarthritis and ... There is no cure for arthritis and no effective ... study could help lead doctors towards a drug to ... molecular pathway and an enzyme that play a pivotal ...
... caused a recent outbreak of Hepatitis A in Pennsylvania ... ,Bill Zavertnik, Chi-Chi's chief operating officer, said in ... were not the source of the outbreak, that there ... outbreak and that it was an isolated incident. , ...
... new study shows a new drug alternative to warfarin in ... The research shows the drug ximelagatran appears to be as ... for people at high risk of stroke because of its ... include an increased risk of bleeding and a possible interaction ...
Cached Medicine News:Health News:Animals can give us a second chance at life 2Health News:HIV Treatment Said to Increase Heart Attack Risk 2Health News:Finding relief from Excruciating Headaches a challenge 2Health News:Finding relief from Excruciating Headaches a challenge 3
(Date:8/27/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ... amniotic tissue and patent-protected processes to develop and ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and ... the multiple inaccuracies in the press release issued ... recent rulings from the Patent Trial and Appeal ...
(Date:8/27/2015)...  Hill-Rom Holdings, Inc., (NYSE: HRC ) invites ... Morgan Stanley Global Healthcare Conference on September 16, 2015, ... to listen to the live discussion via the internet ... https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . A recorded replay of ... conclusion of the live event and accessible via the ...
(Date:8/27/2015)... -- Major pharmaceutical and medical device companies and leading law ... Philadelphia on Oct. 20, discussing issues surrounding ... of HB Litigation Conferences has announced. To ... http://litigationconferences.com/?p=31886 The program is co-chaired by ... Michelle Hart Yeary of Dechert LLP. ...
Breaking Medicine Technology:MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3
... The World Health Organization (WHO) has granted prequalification to ... immunization of infants and children from 6 weeks through ... otitis media caused by the 13 pneumococcal serotypes (1, ... 19A, 19F and 23F) contained in the vaccine. WHO ...
... Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS ; ... financial results for the fiscal 2010 fourth quarter and year ... August 30, 2010. Management has scheduled a ... 30, 2010 (Tuesday, August 31 at 6.30 a.m. AEST) ...
Cached Medicine Technology:World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 2World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 3World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 4World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 5World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 6World Health Organization Grants Prequalification to Prevenar 13*, Pfizer's 13-valent Pneumococcal Conjugate Vaccine for Infants and Young Children 7Unilife Corporation Schedules Fiscal 2010 Fourth Quarter and Year End Conference Call for Monday, August 30, 2010 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: